| P50 | author | Bruce C Trapnell | Q86500814 |
| P2093 | author name string | Bruce C Schnepp | |
| | Philip R Johnson | |
| | Terence R Flotte | |
| | Jeffrey D Chulay | |
| | Guo-Jie Ye | |
| P2860 | cites work | Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue | Q24523651 |
| | Patterns of variant polyadenylation signal usage in human genes | Q24624061 |
| | Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success--a personal perspective | Q27012320 |
| | Genetic fate of recombinant adeno-associated virus vector genomes in muscle | Q33186207 |
| | Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. | Q33823450 |
| | Expression of human alpha1-antitrypsin in mice and dogs following AAV6 vector-mediated gene transfer to the lungs. | Q33930149 |
| | Molecular analysis of vector genome structures after liver transduction by conventional and self-complementary adeno-associated viral serotype vectors in murine and nonhuman primate models | Q34123269 |
| | Characterization of adeno-associated virus genomes isolated from human tissues | Q34142848 |
| | AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 |
| | Preclinical Evaluation of a Recombinant Adeno-Associated Virus Vector Expressing Human Alpha-1 Antitrypsin Made Using a Recombinant Herpes Simplex Virus Production Method | Q34589262 |
| | Gene therapy using adeno-associated virus vectors | Q34852719 |
| | Clinical practice. Alpha1-antitrypsin deficiency | Q34988812 |
| | Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle | Q35054512 |
| | Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results | Q35496285 |
| | Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver | Q36014088 |
| | Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors | Q36734619 |
| | Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle | Q36845715 |
| | The state of the art of adeno-associated virus-based vectors in gene therapy | Q36972714 |
| | Infectious molecular clones of adeno-associated virus isolated directly from human tissues | Q37051580 |
| | AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells | Q37348251 |
| | Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy | Q37364038 |
| | Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression | Q37384103 |
| | Advancements in adeno-associated viral gene therapy approaches: exploring a new horizon | Q37937458 |
| | A review of α1-antitrypsin deficiency | Q37940937 |
| | Current status of gene therapy for α-1 antitrypsin deficiency | Q38264336 |
| | Vector-mediated antibody gene transfer for infectious diseases | Q38372332 |
| | Augmentation therapy of alpha-1 antitrypsin deficiency associated emphysema | Q38439976 |
| | Treatment of Alpha-1 Antitrypsin Deficiency | Q38560001 |
| | Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery | Q39500834 |
| | Formation of adeno-associated virus circular genomes is differentially regulated by adenovirus E4 ORF6 and E2a gene expression. | Q39548622 |
| | In vivo model of adeno-associated virus vector persistence and rescue | Q39874425 |
| | Inverted terminal repeat sequences are important for intermolecular recombination and circularization of adeno-associated virus genomes | Q40726705 |
| | Effects of adeno-associated virus DNA hairpin structure on recombination | Q42755152 |
| | Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients | Q43466855 |
| | Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. | Q43727676 |
| | Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects | Q44136395 |
| | Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults | Q45409947 |
| | High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses | Q45422901 |
| | Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy | Q45428897 |
| | Optimal design of a single recombinant adeno-associated virus derived from serotypes 1 and 2 to achieve more tightly regulated transgene expression from nonhuman primate muscle | Q45668619 |
| | Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo | Q45709105 |
| | Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. | Q45859498 |
| | Sequencing of a urinary stone protein, identical to alpha-one antitrypsin, which lacks 22 amino acids | Q72811350 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vector-borne disease | Q2083837 |
| P304 | page(s) | 32-42 | |
| P577 | publication date | 2015-12-09 | |
| P1433 | published in | Human Gene Therapy | Q15757580 |
| P1476 | title | Recombinant Adeno-Associated Virus Vector Genomes Take the Form of Long-Lived, Transcriptionally Competent Episomes in Human Muscle | |
| P478 | volume | 27 | |